Go to Contents Go to Navigation

Competition fiercer in hypertension drug market with new products

All Headlines 10:33 August 31, 2016

SEOUL, Aug. 31 -- A number of South Korean pharmaceutical firms will release new medications to treat high blood pressure in the local market later this year, as the market has grown to top the landmark 1 trillion won, industry sources said Wednesday.

Noticeably, a number of drugs for hypertension is expected to hit the market as most people with high blood pressure need to take two or more types of medicine to lower it, they said.

"There are many cases when a patient does not control his or her high blood pressure enough with a single medication, leading to high demand for combo drugs," an industry source said.

The domestic market for antihypertensive drugs stands at over 1.2 trillion won (US$1.07 billion), the source said, adding that the market share of combo drugs is also expected to increase.

First, CJ HeathCare Corp. will roll out the company's first combo drug for hypertension in September, they said.

Shinpoong Pharm Co.'s combination medication for hypertension will also hit the shelves in September, they said, noting that the drug has shown good results in clinical trials compared with a single medication.

Boryung Pharmaceutical Co., one of South Korea's largest pharmaceutical companies, said it plans to release a new hypertension drug with triple medication effect.

After more than a decade of research and development, the firm released the country's first homegrown high blood pressure market, Kanarb, earlier.

Boehringer Ingelheim Korea's combo hypertension drug Twinstar is currently the market leader, with its annual sale reaching over 80 billion won.


Send Feedback
How can we improve?
Thanks for your feedback!